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NIH researchers report results of a qHTS hunt for new chemical chaperones for the treatment of
Gaucher disease [1].Lysosomes are cellular recycling cen-
ters. They are sac-like organelles con-
taining largely hydrolytic enzymes that
operate in the low pH environment and
are responsible for the turnover of
cellular constituents within to simple
products for building new molecules.
The construction of the lysosome and
its enzymes is a highly orchestrated
sequence of biosynthetic, targeting,
folding, and trafficking events that
take place in the endoplasmic reticu-
lum and Golgi complex [2]. The result-
ing lysosomes have been engineered
to maintain a kinetic balance of mac-
romolecular recycling for optimal cell
function. A large array of mutations
can disrupt the enzymatic status of
the lysosome, creating an imbalance
that results in the detrimental accumu-
lation of specific macromolecules.
Over 40 such lysosomal storage dis-
eases (LSDs) have been characterized
in humans and are usually categorized
biochemically by accumulated metab-
olite [3].
Gaucher disease is an LSD charac-
terized by an accumulation of the
sphingolipid glucocerebroside due to
a functional deficiency of glucocere-
brosidase (GC; aka acid b-glucosi-
dase). Three types of Gaucher disease
exist differentiated by the degree of
neuronopathology. Symptoms range
from splenomegaly, anemia, and bone
lesions to progressive neurological de-
terioration and death. Enzyme replace-
ment therapy is costly and is not effec-
tive in the treatment of CNSsymptoms.
More than 200 missense mutations
can lead to Gaucher disease; they are
widely distributed throughout the pro-
tein and vary in their frequency and
in the severity of the resulting disease
[4] (Figure 1). Most of these result in
misfolding, decreased stability, and/or
mistrafficking of GC to the lysosome976 Chemistry & Biology 14, September 2[5]. In vitro enzyme activity of GC mu-
tants does not explain the phenotypic
diversity of thediseaseand the instabil-
ity of many variants has led to contro-
versy regarding their activity [6, 7].
The insight underlying the recent
NIH work [1] was provided by the work
of Kelly and colleagues at Scripps in
2002 [8]. Previous work had demon-
strated that chemical chaperones
could induce proper folding and stabi-
lize proteins in the secretory pathway
[9]. The Scripps team posited that
some catalytically active, albeit unsta-
ble, GC mutants might be deficient in
their ability to fold properly or at a kinet-
ically acceptable rate that permits
their effective translocation into the
ER. They might be targeted for proteo-
somal degradation preventing their
trafficking to the lysosome at levels
Figure 1. Mutations in GC Leading to
Gaucher Disease
This figure is adopted from [4]. Position of pre-
viously identified point mutations is mapped
onto the ribbon representation of GC structure.
Residues are color coded as follows: dark red,
residues whose mutation causes severe form
of the disease; bright orange, residues whose
mutation causes mild forms of the disease; in
yellow and dark green, residues that are found
mutated but without clinical data regarding
the severity of the disease. The key active site
residues, E235 and E340, are shown in black
and are not mutated in the disease. Fig-
ure created using PyMOL software (http://
www.pymol.org).007 ª2007 Elsevier Ltd All rights reservedsufficient to prevent accumulation of
the sphingolipid substrate. Using cells
homozygous for the prevalent N370S
mutant of GC [10], the Scripps team
demonstrated that analogs of the
glucosidase inhibitor deoxynojirimy-
cin, an iminosugar found in mulberry
plants, at subinhibitory concentrations
resulted in up to a 2-fold increase in
the GC activity of treated cells. The
data were consistent with the inhibitor
acting as a chemical chaperone to
facilitate the proper folding of the GC
variant, leading to more enzyme suc-
cessfully trafficked to the lysosome.
Additional work has demonstrated
the generality of the iminosugar chap-
erone approach with some, but not all,
GC variants and confirmed increased
GC trafficking to the lysosome [11, 12].
Although the iminosugars studied are
less-than-promising drug candidates,
it was clear that attempts to identify
more drug-like chemical chaperones
for the treatment of Gaucher disease
would soon follow.
The recent NIH screening effort [1]
showcased the development by the
NIH Chemical Genomics Center on
a titration-based, quantitative high-
throughput screening platform (qHTS)
to accelerate the identification of leads
for drug discovery [13]. The platform
was developed to screen compound
libraries at seven or more concentra-
tions (spanning nearly four orders of
magnitude) in a 1536-well plate format
to generate concentration response
curves that would permit the derivation
of SAR directly from the primary library
screen. In addition, the approach also
eliminated false positives and false
negatives common to traditional single
point HTS methods and can provide
relative activities in highly focused li-
braries where single point HTS scores
many compounds as active.
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team screened a library of nearly
60,000 structurally diverse com-
pounds in 7-15 concentrations with a
fluorogenic substrate assay for wild-
type GC activity. The assay was de-
signed to pick up both inhibitors and
activators of GC activity. The screen
yielded 255 active compounds. Clus-
tering and SAR analysis refined the
active compounds into three classes
of inhibitors chosen for further study—
an aminoquinoline, a sulfonamide, and
a triazine series. These series were
expanded through commercially avail-
able analogs. Selected members of
each class were shown to be inhibitors
of GC with the most potent (an amino-
quinoline) having a Ki of 21 nM. Fibro-
blasts homozygous for the N370S GC
mutant showed an enhancement of
GC activity upon compound treat-
ment. The magnitude of enhancement
was comparable to the previous
Scripps iminosugar work although the
NIH compounds showed improved
selectivity against other sugar hydro-
lases. A significant increase in the ly-
sosomal localization of N370S GC
was convincingly demonstrated, sug-
gestive of improved trafficking. The
information-rich qHTS method ap-
pears to reduce the time required to
sort out false positives, to increase
the number of hits by reducing false
negatives, and to permit a more rapid
entry into an SAR analysis. How this
plays out in speed to drug candidate
remains to be evaluated.
A recent Chemistry & Biology article
[14] from a Canadian consortium de-
scribed the traditional HTS screening
of 50,000 compounds for chemical
chaperones (inhibitors) of b-hexosa-
minidase A (Hex), the defective lyso-
somal protein in Tay-Sachs and
Sandhoff diseases. Three structurallyCdistinct and competitive inhibitors
were found with chaperone activity in
patient fibroblasts. One can expect
additional efforts to identify chaperone
leads for other LSDs.
The identification of structurally di-
verse chemical chaperones with cell-
based LSD activity is encouraging
and opens the way for pharmacologi-
cal optimization of lead compounds.
The use of an inhibitor to enhance the
activity of an enzyme is a somewhat
dicey prospect in vivo. Clearly, the
stimulation of properly formed enzyme
by the inhibitor must be balanced
against the direct inhibition of the en-
zyme. Not surprisingly, a bell-shaped
dose response has been observed
for the some of these chaperones
reflecting the opposing functions of
the small molecules but also suggest-
ing that an effective dose can be
achieved. The pulse-chase technique
used in the cell-based chaperone
assays, which stimulates of protein
trafficking (pulse) followed by drug
wash-out (chase) to reduce enzyme in-
hibition, does hint at a pulsatile dosing
regime in patients. Although the NIH
team screened for both inhibitors and
activators, no activators were identi-
fied. Activators, if findable, would ap-
pear to have better therapeutic po-
tential since the downside of enzyme
inhibition would no longer be an issue.
As more compounds are studied and
new assays developed that more
closely approximate defective inter-
mediates in GC processing, it is pos-
sible that chemical chaperones that
avoid active site binding may emerge.
Considerable pharmaceutical work
lies ahead to attain effective drugs
for LSDs. There is little doubt that
the underlying biological problem and
its possible chemical solution have
reached a level of refinement thathemistry & Biology 14, September 2007 ª2bodes well for the new treatments for
these debilitating diseases.
REFERENCES
1. Zheng, W., Padia, J., Urban, D.J., Jadhav,
A., Goker-Alpan, O., Simeonov, A., Goldin,
E., Auld, D., LaMarca, M.E., Inglese, J.,
et al. (2007). Proc. Natl. Acad. Sci. USA
104, 13192–13197.
2. Zhao, H., andGrabowski, G.A. (2002). Cell.
Mol. Life Sci. 59, 694–707.
3. Winchester, B., Vellodi, A., and Young, E.
(2000). Biochem. Soc. Trans. 28, 150–154.
4. Div, H., Harel, M., McCarthy, A.A., Toker,
L., Silman, I., Futerman, A.H., and Suss-
man, J.L. (2003). EMBO Rep. 4, 704–709.
5. Hruska, K.S., LaMarca, M.E., and Sidran-
sky, E. (2006). Gaucher Disease, A.H. Fu-
terman and A. Zimran, eds. (Boca Raton,
FL: CRC Press), pp. 13–48.
6. Beutler, E., and Kuhn, W. (1986). Proc.
Natl. Acad. Sci. USA 83, 7472–7474.
7. Grace, M.E., Newman, K.M., Scheinker,
V., Berg-Fussman, A., and Grabowski,
G.A. (1994). J. Biol. Chem. 269, 2283–
2291.
8. Sawkar, A.R., Cheng, W.-C., Beutler, E.,
Wong, C.-H., Balch, W.E., and Kelly, J.W.
(2002). Proc. Natl. Acad. Sci. USA 99,
15428–15433.
9. Morello, J.P., Bouvier, M., Petaja-Repo,
U.E., andBichet, D.G. (2000). Trends Phar-
macol. Sci. 21, 466–469.
10. Beutler, E., and Gelbart, T. (1993). Br. J.
Haematol. 85, 401–405.
11. Sawkar, A.R., Adamski-Werner, S.L.,
Cheng, W.-C., Wong, C.-H., Beutler, E.,
Zimmer, K.-P., and Kelly, J.W. (2005).
Chem. Biol. 12, 1235–1244.
12. Sawkar, A.R., Schmitz, M., Zimmer, K.-P.,
Reczek, D., Edmunds, T., Balch, W.E., and
Kelly, J.W. (2006). ACSChem. Biol. 1, 235–
251.
13. Inglese, J., Auld, D.S., Jadhav, A., John-
son, R.L., Simeonov, A., Yasgar, A.,
Zheng, W., and Austin, C.P. (2006). Proc.
Natl. Acad. Sci. USA 103, 11473–11478.
14. Tropak, M.B., Blanchard, J.E., Withers,
S.G., Brown, E.D., and Mahuran, D.
(2007). Chem. Biol. 14, 153–164.007 Elsevier Ltd All rights reserved 977
